GenMark

The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in the first half of the year.

The GenomeWeb Index rose more than 2 percent in June, but the increase was subdued compared to the index's 9 percent climb in May and 18 percent hike in April.

The GenomeWeb Index rose more than 9 percent in May, following an 18 percent climb in April, a marked contrast to its negative performance in February and March.

GenMark said it intends to use the proceeds for general corporate purposes that may include an expansion of its menu and increasing its manufacturing capacity.

The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.

In a marked contrast to its negative performance in February and March, the GenomeWeb Index rose more than 18 percent in April.

Approximately 80 percent of gross product placements in the quarter were associated with interest in COVID-19 testing, the firm said

The GenomeWeb Index fared better than its benchmark counterparts in March, but still fell more than 4 percent.

The firm now expects to complete the development work needed to request Emergency Use Authorization for the new panel.